Tandutinib

N/A

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug NameTandutinib
Drug Alias Nametandutinibum坦度替尼MLN-518MLN-0518CT-53518
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPlatelet-derived growth factor receptor alpha inhibitorsStem cell growth factor receptor inhibitorsTyrosine-protein kinase receptor FLT3 inhibitors +[4] 
TargetsStem cell growth factor receptorPlatelet-derived growth factor receptor betaTyrosine-protein kinase receptor FLT3 +[4] 
Therapy Area/IndicationsPainMyelodysplastic SyndromesNeoplasm Metastasis +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTakeda Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Cancer InstituteMillennium Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsPainMyelodysplastic SyndromesNeoplasm Metastasis +[11] 

Other Information

ATC CodeN/A
Related LinksKEGG